background. The S-Caine peel (Zars, Inc., Salt Lake City, UT) is a novel eutectic lidocaine/tetracaine mixture that is applied as a cream, drying upon exposure to air to form a flexible film that can be peeled off easily. The patented formulation can be used to anesthetize the skin prior to a variety of cutaneous procedures. objective. To examine the clinical efficacy of the S-Caine peel as a topical anesthetic for pulsed dye laser (PDL) treatment and to determine the optimal application time for adequate cutaneous anesthesia. methods. Sixty patients were enrolled in one of three separate double-blind, placebo-controlled protocols in which the active product or a placebo was applied to the skin and left intact for 20, 30, or 60 minutes prior to laser treatment. A 585 nm or 595
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THERE ARE a variety of local anesthetics available to reduce the discomfort associated with cutaneous laser surgery. [1] [2] [3] [4] Local anesthesia can be administered by injection or through the use of topical creams and ointments. Injectable anesthetics are often as painful as the laser procedure itself and are difficult to use in "needlephobic" patients, whereas topical anesthetics are limited by the lengthy application period, often under occlusion, that is necessary to achieve the desired effect. [5] [6] [7] [8] [9] [10] [11] The S-Caine peel is a new drug currently under clinical investigation. The patented eutectic lidocaine/tetracaine cream mixture is air dried to form a flexible film on the skin that can be peeled away easily. The aim of this study was to determine the clinical efficacy of the S-Caine peel as a topical anesthetic prior to pulsed dye laser (PDL) treatment for vascular lesions on the face. Three separate protocols were developed in order to assess the optimal application time for cutaneous anesthesia.
Materials and Methods
Sixty patients (49 female, 11 male, ages 18-70 years, skin phototypes I-IV) with benign vascular lesions including portwine stains and telangiectases were enrolled in three separate protocols (Table 1) . Patient exclusion criteria included sensitivity to lidocaine, tetracaine, or other amide-ester anesthetics, intake of concomitant analgesic medication during the preceding 24 hours, damaged or broken skin at the designated treatment site, and concomitant pregnancy or lactation.
In the first protocol, 30 patients were randomized to receive either the active drug (S-Caine peel) or a placebo applied to the skin for 60 minutes. The clinical investigator performing the laser treatment (T.S.A.) and the patient were blinded to the actual cream used. The product was evenly applied to the treatment area using a spatula, producing a 2 mm thick layer of cream on the skin. After 60 minutes the air-dried product was peeled away from the treatment area ( Figure 1 ). The patient's skin was evaluated for side effects, including erythema, edema, and skin blanching ( Table 2) . A 595 nm PDL was then used to treat the specified facial areas (7 mm spot size, 1.5-msec pulse duration, 25-100 pulses per site) within 5 minutes of product removal ( Table  3 ). The patients were asked to evaluate the level of pain experienced during the laser treatment on a visual analog scale ( Figure 2 ). Similarly the blinded investigator's and independent observer's evaluations of pain experienced by the pa-tient were recorded (Table 4) . If the patient's lesion required more than 100 pulses, laser treatment was stopped until the patient, the clinical investigator, and the independent observer had each recorded their pain evaluations.
The second and third protocols involved 15 patients, each of whom were randomized to application of the active drug (S-Caine peel) or a placebo to the skin for either 20 or 30 minutes. The patient's skin was evaluated for side effects after removal of the active or placebo drug by the blinded clinical investigator ( Table 2) . The areas were then treated with a 585 nm PDL using a 7 mm, 10 mm, or 2 mm ϫ 7 mm spot size, 1.5-msec pulse duration, and 50-125 laser pulses (Table 3 ). The patient, blinded clinical investigator, and independent observer each evaluated the level of pain experienced using the scales outlined in Figure 2 and Table 4 .
Results
All patients who received the active drug experienced significantly less pain than those patients who received the placebo. Mean patient pain ratings using the VAS revealed similar results for all three protocols ( Table 5 ). The patients in protocol A receiving the active drug for 60 minutes had a mean VAS score of 14.4 mm (com- pared to 33.9 mm for controls). Mean pain ratings of 13.1 mm and 12.4 mm were reported by patients in protocol B (active drug for 20 minutes) and protocol C (active drug for 30 minutes), respectively (compared to 56.0 and 60.8 mm, respectively, for controls). Three of the 36 patients (9%) who received the active drug stated that they did not have adequate pain relief, whereas 17 of 24 (66%) placebo group patients reported inadequate pain relief. Of the active drug patients tested, 32 of 36 (88%) stated their desire to use the S-Caine peel again if given the option ( Table 5) .
The blinded investigator's evaluation rated 27 of 36 (75%) active drug patients with no pain and 9 of the 36 (25%) patients with slight pain. Similarly the independent observer's evaluation rated 26 of the 36 active drug patients with no pain and 10 of the 36 patients with slight pain. No observations of moderate or severe pain were made in the active drug group. In the placebo group ( n ϭ 24), the blinded investigator rated 2 patients demonstrating no pain, 13 with slight pain, and 9 with moderate pain. Similarly the independent observer rated 2 patients as having no pain, 12 with slight pain, and 10 with moderate pain. No observations of severe pain were made (Table 6) .
Pain ratings (VAS scores) of less than 20 mm were made by 72.2% of active drug patients. Average VAS scores less than 10 mm were reported in 52.8% of Number of patients  16  14  10  5  10  5  Investigator's evaluation  No pain  12  2  7  0  8  0  Slight pain  4  9  3  2  2  2  Moderate pain  0  3  0  3  0  3  Severe pain  0  0  0  0  0  0  Independent observer's evaluation  No pain  12  2  6  0  8  0  Slight pain  4  8  4  3  2  1  Moderate pain  0  4  0  2  0  4  Severe pain  0  0  0  0  0  0 those patients. In the placebo group, 16.6% of the patients had VAS scores less than 20 mm and 8.3% less than 10 mm. Accordingly the blinded investigator observed 75% of the active drug group with no pain and 8.3% of the placebo group with no pain. The independent observer rated 72.2% of the patients using active drug as demonstrating no pain and 8.3% of those using placebo with no pain (Figure 3 ). Side effects were limited to mild erythema, with two of the active patients in the 20-minute protocol ( n ϭ 10) and two of the placebo patients (one in the 20-minute and one in the 30-minute protocol) displaying well-defined erythema (Table 7) . No instances of edema or blanching were reported or observed.
Discussion
The use of topical anesthetic agents to decrease pain associated with a variety of cutaneous laser procedures has been shown to be effective in a number of studies. 5, [7] [8] [9] [10] The average time of application in order to achieve adequate anesthesia typically exceeds 60 minutes, limiting the practical use of these creams and gels in a busy clinical practice. [5] [6] [7] [8] [9] [10] Our study of a novel anesthetic delivery system (S-Caine peel) demonstrated quick and effective anesthesia for cutaneous PDL treatment. Significant differences in pain scores were seen in all areas receiving the anesthetic peel compared to those without (controls). Side effects of peel application were limited to transient mild erythema. Equivalent levels of pain reduction were experienced and/or observed at 20-, 30-, and 60-minute application times of active drug, suggesting that the flexible film that forms when the S-Caine cream dries may serve as an occlusive dressing that facilitates drug absorption and/or deposition in the skin. When compared to the prolonged application times required for good clinical efficacy of other available topical anesthetic agents, 10 the S-Caine peel provides a neat and effective alternative.
The high level of efficacy and patient satisfaction of the S-Caine peel demonstrated in this study should be confirmed by further clinical evaluation. In particular, its quick mode of action may render the S-Caine peel of great benefit in a host of pediatric medical procedures. In addition, its potential use in cutaneous laser resurfacing may preclude the need for intravenous sedation in single-pass procedures. 
Conclusion
The S-Caine peel can provide adequate cutaneous anesthesia for PDL treatment when applied to the skin for as little as 20 minutes preoperatively. Its use for other dermatologic procedures needs further study.
